Table 1 Characteristics of trial cohort
Category | Number of trials (N = 151) | Percent total (%) | Median (IQR) anticipated enrollmenta | Median (IQR) actual enrollmentb |
|---|---|---|---|---|
Trial phase | ||||
Phase 2c | 103 | 68.21 | 100 (44–200) | 48 (20–100) |
Phase 3d | 48 | 31.79 | 400 (263–600) | 243 (143–1088) |
Randomization | ||||
Randomized | 129 | 85.43 | 200 (60–400) | 110 (41–236) |
Non-randomized | 8 | 5.30 | 68 (20–158) | 20 (18–23) |
NAe | 14 | 9.27 | 47 (26–100) | 33 (13–49) |
Trial statusf | ||||
Completed | 12 | 7.95 | 397 (58–503) | 81 (29–1075) |
Terminated | 4 | 2.65 | 279 (54–625) | 51 (36–63) |
Active, not recruiting | 27 | 17.88 | 120 (43–289) | 86 (32–175) |
Recruiting | 99 | 65.56 | 138 (60–329) | 196 (20–225) |
Enrolling by invitation | 4 | 2.65 | 400 (230–515) | None |
Suspended | 5 | 3.31 | 500 (200–600) | 1 (1–1) |
Sponsorship | ||||
Industry sponsor | 51 | 33.77 | 200 (84–385) | 130 (59–231) |
Non-industry sponsor | 100 | 66.23 | 136 (50–500) | 50 (19–225) |
Number of centers | ||||
Single center | 58 | 38.41 | 100 (41–255) | 24 (17–50) |
Multicenter | 93 | 61.59 | 208 (80–400) | 140 (50–243) |